Drugs / Autologous adipose-derived SVF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06304623 | May 2020 → Mar 2024 | pulmonary fibrosis | Michael H Carstens | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous adipose-derived SVF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06304623 ↗ |
| Modality | Cell therapy | “cellular therapy with SVF cells” NCT06304623 ↗ |
| Route | Intravenous | “Subjects received an intravenous injection of autologous adipose-derived SVF.” NCT06304623 ↗ |